Initial results of phase 1/2 study CC-92480-MM-002 onCELMoD CC-92480 in combination with bortezomib (BORT)and dexamethasone (DEX) in patients with relapsed /refractory multiple myeloma (RRMM)

被引：0
|
作者：
Raab, M. -S. [1 ]
Richardson, P. G. [2 ]
Ocio, E. M. [3 ]
Raje, N. [4 ]
Gregory, T. [5 ]
White, D. [6 ,7 ]
Oriol, A. [8 ,9 ]
Sandhu, I. [10 ]
LeBlanc, R. [11 ]
Rodriguez Valdes, C. [12 ]
Trudel, S. [13 ]
Waesch, R. [14 ]
Perrot, A. [15 ]
Bahlis, N. J. [16 ]
Zhou, Z. [17 ]
Lamba, M. [17 ]
Amatangelo, M. [17 ]
Civardi, T. [18 ]
Katz, J. [17 ]
Maciag, P. [17 ]
Peluso, T. [18 ]
Dimopoulos, M. A. [19 ]
机构：
[1] Univ Klinikum Heidelberg, Heidelberg, Germany
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Hosp Univ Marques De Valdecilla IDIVAL, Santander, Spain
[4] Massachusetts Gen Hosp, Boston, MA USA
[5] Colorado Blood Canc Inst, Denver, CO USA
[6] Dalhousie Univ, Halifax, NS, Canada
[7] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[8] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain
[9] Hosp Badalona Germans Trias & Pujol, Josep Carreras Inst, Badalona, Spain
[10] Univ Alberta, Edmonton, AB, Canada
[11] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada
[12] Wake Forest Baptist Hlth, Winston Salem, NC USA
[13] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[14] Univ Klinikum Freiburg, Freiburg, Germany
[15] Inst Univ Canc Toulouse Oncopole, Toulouse, France
[16] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[17] Bristol Myers Squibb, Princeton, NJ USA
[18] Celgene Int Sarl, Bristol Myers Squibb Co, Boudry, Switzerland
[19] Alexandria Gen Hosp, Athens, Greece
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P308
引用
收藏
页码：86 / 86
页数：1
相关论文
共 50 条
  • [41] PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM)
    Alsina, M.
    Lonial, S.
    Weber, D. M.
    Coutre, S. E.
    Kang, B. P.
    Glynos, T.
    Warsi, G.
    Snodgrass, S. M.
    Richardson, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)
    Vogl, Dan T.
    Raje, Noopur
    Hari, Parameswaran
    Jones, Simon S.
    Supko, Jeffrey G.
    Leone, Gina
    Wheeler, Catherine
    Orlowski, Robert Z.
    Richardson, Paul G.
    Lonial, Sagar
    Tamang, David
    Jagannath, Sundar
    BLOOD, 2014, 124 (21)
  • [43] A Phase 1b/2a Study of the CELMoD Iberdomide (CC-220) in Combination With Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    Van de Donk, Niels
    Popat, Rakesh
    Zonder, Jeffrey A.
    Minnema, Monique
    Larsen, Jeremy T.
    Tuong Vi Nguyen
    Chen, Min S.
    Bensmaine, Amine
    Peluso, Teresa
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E52 - E53
  • [44] PANORAMA 2: A PHASE II STUDY OF PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED AND BORTEZOMIB-REFRACTORY MULTIPLE MYELOMA
    Richardson, P.
    Alsina, M.
    Weber, D.
    Coutre, S.
    Lonial, S.
    Gasparetto, C.
    Warsi, G.
    Ondovik, M.
    Mukhopadhyay, S.
    Paley, C.
    Schlossman, R.
    HAEMATOLOGICA, 2012, 97 : 338 - 338
  • [45] Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)
    Baz, Rachid
    Zonder, Jeffrey A.
    Shain, Kenneth H.
    Alsina, Melissa
    Brayer, Jason B.
    Melody, Mark
    Turner, Joel G.
    Dawson, Jana L.
    Kim, Jongphil
    Sullivan, Daniel M.
    BLOOD, 2017, 130
  • [46] Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results
    Vij, Ravi
    Huff, Carol Ann
    Bensinger, William I.
    Siegel, David S.
    Jagannath, Sundar
    Berdeja, Jesus
    Lendvai, Nikoletta
    Lebovic, Daniel
    Anderson, Larry D.
    Costello, Caitlin L.
    Stockerl-Goldstein, Keith E.
    Laubach, Jacob P.
    Elias, Laurence
    Clow, Fong
    Fardis, Maria
    Graef, Thorsten
    Bilotti, Elizabeth
    Richardson, Paul G.
    BLOOD, 2014, 124 (21)
  • [47] Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial
    Lonial, Sagar
    Abdallah, Al-Ola
    Anwer, Faiz
    Badros, Ashraf Z.
    Bhutani, Manisha
    Khan, Abdullah
    Lipe, Brea
    Oriol, Albert
    White, Darrell
    Amatangelo, Michael
    Jin, Kexin
    Masin, Mark
    Nguyen, Vi
    Amin, Alpesh
    Maciag, Paulo
    van de Donk, Niels W. C. J.
    BLOOD, 2022, 140 : 4398 - 4400
  • [48] A multicenter phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (Dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM).
    Richardson, Paul
    Lonial, S.
    Jakubowiak, A.
    Wolf, J.
    Krishnan, A.
    Densmore, J.
    Singhal, S.
    Ghobrial, I.
    Schwartzberg, L.
    Colson, K.
    Harris, J.
    Kendall, T.
    Martineau, I.
    Obadike, N.
    Sullivan, K.
    Pearson, S.
    Hideshima, T.
    Lai, L.
    Sportelli, P.
    Gardner, L.
    Birch, R.
    Henderson, I. C.
    Anderson, K. C.
    BLOOD, 2006, 108 (11) : 1023A - 1023A
  • [49] A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Kumar, Shaji
    Harrison, Simon J.
    Cavo, Michele
    De La Rubia, Javier
    Popat, Rakesh
    Gasparetto, Cristina J.
    Hungria, Vania
    Salwender, Hans J.
    Suzuki, Kenshi
    Kim, Inho
    Punnoose, Elizabeth
    Hong, Wan-Jen
    Freise, Kevin J.
    Sood, Anjla
    Jalaluddin, Muhammad
    Ross, Jeremy
    Ward, James E.
    Maciag, Paulo
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E31 - E31
  • [50] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Ocio, Enrique M.
    Mateos, Maria-Victoria
    Prosper, Felipe
    Martin, Jesus
    Rocafiguera, Albert Oriol
    Jarque, Isidro
    Iglesias, Rebeca
    Motlloo, Cristina
    Sole, Maria
    Rodriguez-Otero, Paula
    Martinez, Sara
    Fernandez-Garcia, Eva
    Michot, Jean-Marie
    Soto-Matos, Arturo
    Diaz-Pavon, Jose Rodriguez
    Ribrag, Vincent
    Miguel, Jesus San
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345